Buchumschlag

Research Communication: Combination Therapy of Upadacitinib With Infliximab, Risankizumab, Ustekinumab or Vedolizumab for Refractory Crohn's Disease: A Descriptive Case Series

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Rahul S. Dalal, Lindsay M. Clarke, Heidy J. Cabral, Alexander D. Carlin, Grace B. Hardwick, Jessica R. Allegretti
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2025
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Review article: The epidemiology and management of Clostridioides difficile infection—A clinical update
von: Lindsay M. Clarke, et al.
Veröffentlicht: (2024)

Editorial: Upadacitinib in Perianal Crohn's Disease
von: Manjeet Kumar Goyal, et al.
Veröffentlicht: (2026)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease?
von: C. Ramos‐Belinchon, et al.
Veröffentlicht: (2025)

Editorial: Real‐World Evidence of Upadacitinib—An Effective Induction Therapy for Crohn's Disease? Authors' Reply
von: Nicolas Richard, et al.
Veröffentlicht: (2025)

Long‐Term Outcomes of an Infliximab‐First Versus Vedolizumab‐First Treatment Strategy in Biologic‐Naïve Patients With Ulcerative Colitis
von: Austin Haynesworth, et al.
Veröffentlicht: (2024)

Editorial: Upadacitinib—A Promising Induction Agent for Paediatric Crohn's Disease?
von: Vincenzo Stranges, et al.
Veröffentlicht: (2025)

Editorial: Infliximab induction therapy in pediatric Crohn's disease—A cost‐effective strategy?
von: Neil Chanchlani, et al.
Veröffentlicht: (2024)

Efficacy and Safety of Vedolizumab and Tofacitinib ( VETO ) Combination Therapy in Refractory Ulcerative Colitis Unresponsive to Anti‐ TNF and a Second‐Line Advanced Therapy: A Prospective Cohort Nested Within a Randomised Trial
von: Pardhu Bharath Neelam, et al.
Veröffentlicht: (2025)

Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study
von: Shlomi Cohen, et al.
Veröffentlicht: (2025)

Editorial: Infliximab induction therapy in paediatric Crohn's disease — A cost‐effective strategy? Authors' reply
von: Stephanie A. Vuijk, et al.
Veröffentlicht: (2024)

One‐Year Effectiveness of Upadacitinib in Perianal Crohn's Disease: A Real‐World GETAID Study
von: Nicolas Richard, et al.
Veröffentlicht: (2026)

The use of opioids nine months after surgery for Crohn's disease – a nationwide cohort study
von: Bente Mertz Nørgård, et al.
Veröffentlicht: (2024)

Editorial: Effectiveness and Safety of Ustekinumab in Ulcerative Colitis—Where We Are Now in Real Life. Authors' Reply
von: María Chaparro, et al.
Veröffentlicht: (2024)

Systemic Biologics Have Similar Safety to Vedolizumab in Inflammatory Bowel Disease Patients Following Liver Transplantation
von: Simone Chin, et al.
Veröffentlicht: (2025)

Editorial: Mesenchymal Stem Cell Therapy for Perianal Fistulising Crohn's Disease—Effective or Hype?
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2024)

Editorial: Dual Advanced Therapy in Refractory Ulcerative Colitis—Hope Beyond Monotherapy
von: Ahmed B. Bayoumy, et al.
Veröffentlicht: (2025)

Editorial: Is There a Role for Therapeutic Drug Monitoring of Subcutaneous Infliximab in Patients With Inflammatory Bowel Disease?
von: Konstantinos Papamichael, et al.
Veröffentlicht: (2024)

Correction to ‘Stromal Vascular Fraction With Platelet‐Rich Plasma Injection During Surgery is Feasible and Safe in Treatment‐Refractory Perianal Fistulising Crohn's Disease: A Pilot Study’
Veröffentlicht: (2024)

Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab: Results From the VedoKids Prospective Multicentre Study
von: Ronen Stein, et al.
Veröffentlicht: (2025)

Clinical Trial: Association Between Early Disease Clearance and Long‐Term Outcomes—4‐Year Results From the Phase 3 UNIFI Study of Ustekinumab in Ulcerative Colitis
von: Silvio Danese, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
von: Tamar Schildkraut, et al.
Veröffentlicht: (2024)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity?
von: Xiao‐Dong Zhou, et al.
Veröffentlicht: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
von: Kuan‐Ju Lin, et al.
Veröffentlicht: (2025)

Performance of bowel preparation quality scales in patients with Crohn's disease
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Antoine Meyer, et al.
Veröffentlicht: (2025)

Editorial: The prevalence and outcomes of perianal Crohn's disease across treatment eras
von: Daniel Tassone, et al.
Veröffentlicht: (2024)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
von: Zhidong Zhou, et al.
Veröffentlicht: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease—Authors' Reply
von: Virginia Solitano, et al.
Veröffentlicht: (2024)

Editorial: Seton Use in Perianal Fistulising Crohn's Disease. Authors' Reply
von: Jeffrey D McCurdy, et al.
Veröffentlicht: (2025)

Editorial: Combination Therapies for MASH : A Step Forward or More Complexity? Authors' Reply
von: Eric Lawitz, et al.
Veröffentlicht: (2025)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
von: Stergios A. Polyzos, et al.
Veröffentlicht: (2024)

Editorial: Examining Perianal Fistulising Crohn's Disease Through the Lens of Wound Repair
von: Tim Eglinton
Veröffentlicht: (2025)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
von: Ziheng Calvin Xu, et al.
Veröffentlicht: (2025)

Editorial: Endoscopic Activity is an Essential Tool for Patients' Management, Even in Mild Crohn's Disease
von: Marco Mendolaro, et al.
Veröffentlicht: (2025)

Letter: Putting Crohn's Risk Prediction to Work in Perianal Fistula—Calibration, Thresholds, and Transport
von: Emmanuel Pio Pastore
Veröffentlicht: (2025)

Editorial: Beyond Resection—Rethinking Postoperative Management in Colonic Crohn's Disease. Authors' Reply
von: José Luis Rueda García, et al.
Veröffentlicht: (2026)

Systematic review: Defining, diagnosing and monitoring small bowel strictures in Crohn's disease on intestinal ultrasound
von: Cathy Lu, et al.
Veröffentlicht: (2024)

Letter: Gut microbiota—An overlooked therapeutic target in the prevention of post‐operative recurrence of Crohn's disease
von: D. Bogatic, et al.
Veröffentlicht: (2024)

Early ileal resection in Crohn's disease is not associated with severe long‐term outcomes: The ERIC study
von: Nathan Grellier, et al.
Veröffentlicht: (2024)

Fistula Calprotectin as a Biomarker of Local Inflammation and Treatment Response in Perianal Fistulizing Crohn's Disease
von: Runqi Wang, et al.
Veröffentlicht: (2026)